Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.36%
1,096.72
+3.98
+0.36%
—1,092.741,095.951,103.321,094.72——
SIXC
Communications
SIXC
Communications
SIXC
-0.33%
611.32
-2.04
-0.33%
—613.36613.36613.36609.50——
SIXE
Energy
SIXE
Energy
SIXE
-0.45%
1,171.54
-5.25
-0.45%
—1,176.791,176.521,182.251,166.69——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.45%
1,747.63
-7.91
-0.45%
—1,755.541,759.231,766.301,746.04——
SIXM
Financials
SIXM
Financials
SIXM
-0.58%
631.49
-3.66
-0.58%
—635.15635.20636.89630.09——
SIXR
Staples
SIXR
Staples
SIXR
+0.23%
849.94
+1.93
+0.23%
—848.01852.52855.78849.58——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.09%
218.06
+0.20
+0.09%
—217.86217.86219.52217.86——
SIXT
Technology
SIXT
Technology
SIXT
+3.47%
3,536.03
+118.68
+3.47%
—3,417.353,452.773,536.033,450.39——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.91%
905.07
-8.29
-0.91%
—913.36915.10920.43904.57——
SIXV
Health care
SIXV
Health care
SIXV
-0.86%
1,449.86
-12.52
-0.86%
—1,462.381,461.131,464.531,446.02——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.30%
2,430.47
+7.33
+0.30%
—2,423.142,428.712,448.692,424.63——
084990:KOSDAQ
Helixmith Co Ltd
â‚©7,920.00
-5.15%
(-430.00) 1D
May 8, 3:30:03 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 084990...
Open
â‚©8,370
High
â‚©8,690
Low
â‚©7,540
Mkt. cap
365.05B
Avg. vol.
916.35K
Volume
0.00
52-wk high
â‚©9,960
52-wk low
â‚©2,540
EPS
-â‚©9
Shares outstanding
46.09M
No. of employees
38
News stories
From sources across the web
Profile
Helixmith Co. LTD. is a biotechnology company located in Seoul, South Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis, currently in phase III diabetic peripheral neuropathy in the US. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor, HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers, amyotrophic lateral sclerosis, coronary artery disease, claudication, and Charcot-Marie-Tooth disease. Wikipedia
About Helixmith Co Ltd
CEO-
Employees38
FoundedNov 1996
Headquarters-
SectorBiotechnology
Websitehelixmith.com
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
930.47M
612.74M
564.70M
490.24M
Cost of goods sold
651.80M
389.25M
400.78M
231.01M
Cost of revenue
651.80M
389.25M
400.78M
231.01M
Research and development expenses
1.04B
333.02M
652.85M
535.63M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.85B
1.57B
1.86B
1.89B
Operating expense
3.14B
2.21B
2.84B
2.62B
Total operating expenses
3.79B
2.60B
3.24B
2.85B
Operating income
-2.86B
-1.99B
-2.68B
-2.36B
Other non operating income
332.37M
-101.22M
79.76M
3.48B
EBT including unusual items
-1.54B
-769.52M
-1.02B
2.87B
EBT excluding unusual items
-1.65B
-1.56B
-2.65B
3.96B
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
14.35M
7.08M
169.35M
6.21M
Net income
-1.53B
-762.34M
-1.02B
2.87B
Net profit margin
-164.30%
-124.42%
-180.11%
586.11%
Earnings per share
-
-
-
-
Interest and investment income
743.90M
209.75M
93.74M
2.99B
Interest expense
-1.63M
-1.50M
-1.37M
-1.24M
Net interest expenses
742.27M
208.25M
92.36M
2.99B
Depreciation and amortization charges
233.66M
219.00M
224.35M
210.70M
EBITDA
-2.32B
-1.53B
-2.27B
-1.95B
Gain or loss from assets sale
-31.32M
-27.66M
-13.16M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer